Despite advances in ALK inhibition, resistance remains an important challenge in metastatic ALK+ non-small cell lung cancer (NSCLC). Dr. Alice Shaw, Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, explores patterns of disease progression, emerging on- and off-target resistance mechanisms, and the potential role of combination approaches in overcoming resistance.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
